



**ALLERGAN**  
**LEGAL DEPARTMENT**  
2525 Dupont Drive  
Irvine, California 92612  
Telephone: (714) 246-4669  
Fax No.: (714) 246-4249

TO: Examiner: M. Cebulak  
Telephone:  
FAX: 703-308-7921

FROM: Robert J. Baran  
Telephone-714-246-4669  
FAX NO.: 714-246-4249

DATE: June 16, 1997

cc:

Pages being sent including this cover page:6

**CONFIDENTIAL / ATTORNEY CLIENT PRIVILEGED COMMUNICATION**

☒ ORIGINAL WILL NOT FOLLOW

☐ ORIGINAL WILL FOLLOW VIA:

☐ Regular Mail

☐ Overnight Delivery

☐ Hand Delivery

☐ Other

This fax has been sent to one number only- please copy ALL OTHER addressees in your location/country.

As discussed by telephone on June 13, 1997, attached is an amendment for Serial No. 08/605,567 (Docket No. 16955DIVCONCIP(AP)). Please call if you have any questions.

Robert J. Baran  
Reg. No. 25,806

**CONFIDENTIALITY NOTE:** The information contained in this facsimile message is privileged or confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is neither allowed or intended. If you have received this communication in error, please immediately notify us by telephone at the below number, and return the original message to us at the below address via the US. Postal Service. Thank you.

DOCKET NO. 16955DIV1CON(AP)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:  
Woodward, et.al.

Group Art Unit: 1204

Serial No: 08/371,339

Examiner: A. Siegel

Filed: January 11, 1995

For: NON-ACIDIC  
CYCLOPENTANE HEPTANOIC ACID,  
2-CYCLOALKYL OR ARYLALKYL  
DERIVATIVES AS THERAPEUTIC  
AGENTS

TRANSMITTAL LETTER

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.

☒ No additional fee is required.

☐ The fee has been calculated as shown below:

CLAIMS	COLUMN A Claims Remaining After Amendment	COLUMN B Highest Number Previously Paid For	COLUMN C Extra	Rate	Fee
Total	29	30	= 0	x \$22	0.00
Independent	4	3	= 1	x \$78	78.00
<input type="checkbox"/> First Presentation of Multiple Dep. Claim x \$250 =					
					Total Additional Fee \$0.00

- \* If the entry in Col. A is less than the entry in Col. B, write '0' in Col. C  
 \*\* If the highest number previously paid for IN THIS SPACE is less than 20,  
 write '20' in this space  
 \*\*\* If the highest number previously paid for IN THIS SPACE is less than 3,  
 write '3' in this space

#10/B

Uce  
6/17/9716955DIVCONCIP(AP)  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT

In Re Application of

Woodward et al

Serial No: 08/605,567

Filed: February 22, 1996

For: CYCLOPENTANE HEPTANOIC  
ACID, 2-CYCLOALKYL OR  
ARYLALKYL DERIVATIVES AS  
THERAPEUTIC AGENTS

Group Art Unit: 1209

Examiner: M. Cebulak

AMENDMENTHonorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

In response to a telephone conversation with the Examiner on June 13, 1997, the following amendment is offered:

Please cancel claims 1 through 4.

Claim ~~5~~ (Amended) [The method of claim 4 wherein said compound is  
a) A method of treating ocular hypertension or glaucoma which comprises  
applying to the eye an amount sufficient to treat ocular hypertension or  
glaucoma of a compound represented by the formula V

